Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent Form~* Age ≥18 years~* Histologically documented adenocarcinoma of the breast with locally recurrent or metastatic disease~  o Patients with breast cancer overexpressing HER2 are not eligible.~* Availability of tumor tissue, either archival FFPE or obtained at study entry through fresh biopsy~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* All acute treatment-related toxicity from prior therapy must have resolved to Grade ≤ 1 prior to study entry~* Adequate hematologic and end-organ function~* Evaluable or measurable disease per RECIST v1.1~* For women of childbearing potential, agreement to use two effective forms of contraception~Exclusion Criteria:~* Known significant dose delays during prior treatment with a taxane due to drug-related toxicities~* Prior treatment with more than two regimens of systemic cytotoxic chemotherapy for locally recurrent or metastatic disease~* Treatment with any anti-cancer therapy within 3 weeks prior to initiation of study treatment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Vantictumab combined with paclitaxel (Type: EXPERIMENTAL): Drug: vantictumab combined with paclitaxel - administered intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).